Twist Bioscience Corporat... (TWST)
Twist Bioscience Statistics
Share Statistics
Twist Bioscience has 59.65M shares outstanding. The number of shares has increased by 3.87% in one year.
| Shares Outstanding | 59.65M |
| Shares Change (YoY) | 3.87% |
| Shares Change (QoQ) | 1.31% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 56.37M |
| Failed to Deliver (FTD) Shares | 1.21K |
| FTD / Avg. Volume | 0.13% |
Short Selling Information
The latest short interest is 9.02M, so 15.14% of the outstanding shares have been sold short.
| Short Interest | 9.02M |
| Short % of Shares Out | 15.14% |
| Short % of Float | 16.03% |
| Short Ratio (days to cover) | 15.97 |
Valuation Ratios
The PE ratio is -12.56 and the forward PE ratio is -25.49. Twist Bioscience's PEG ratio is 0.
| PE Ratio | -12.56 |
| Forward PE | -25.49 |
| PS Ratio | 8.38 |
| Forward PS | 3.5 |
| PB Ratio | 5.55 |
| P/FCF Ratio | -37.89 |
| PEG Ratio | 0 |
Enterprise Valuation
Twist Bioscience Corporation has an Enterprise Value (EV) of 960.09M.
| EV / Earnings | -4.6 |
| EV / Sales | 3.07 |
| EV / EBITDA | -5.43 |
| EV / EBIT | -4.35 |
| EV / FCF | -13.88 |
Financial Position
The company has a current ratio of 4.88, with a Debt / Equity ratio of 0.18.
| Current Ratio | 4.88 |
| Quick Ratio | 4.54 |
| Debt / Equity | 0.18 |
| Total Debt / Capitalization | 15.25 |
| Cash Flow / Debt | -0.75 |
| Interest Coverage | -7614.86 |
Financial Efficiency
Return on equity (ROE) is -0.44% and return on capital (ROIC) is -39.7%.
| Return on Equity (ROE) | -0.44% |
| Return on Assets (ROA) | -0.34% |
| Return on Capital (ROIC) | -39.7% |
| Revenue Per Employee | $339,083.42 |
| Profits Per Employee | $-226,138.68 |
| Employee Count | 923 |
| Asset Turnover | 0.51 |
| Inventory Turnover | 7.46 |
Taxes
| Income Tax | 560K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 21.19% in the last 52 weeks. The beta is 2.15, so Twist Bioscience's price volatility has been higher than the market average.
| Beta | 2.15 |
| 52-Week Price Change | 21.19% |
| 50-Day Moving Average | 45.22 |
| 200-Day Moving Average | 46.28 |
| Relative Strength Index (RSI) | 47.71 |
| Average Volume (20 Days) | 966.14K |
Income Statement
In the last 12 months, Twist Bioscience had revenue of 312.97M and earned -208.73M in profits. Earnings per share was -3.6.
| Revenue | 312.97M |
| Gross Profit | 133.35M |
| Operating Income | -220.83M |
| Net Income | -208.73M |
| EBITDA | -176.71M |
| EBIT | -220.83M |
| Earnings Per Share (EPS) | -3.6 |
Balance Sheet
The company has 226.32M in cash and 85.03M in debt, giving a net cash position of 141.29M.
| Cash & Cash Equivalents | 226.32M |
| Total Debt | 85.03M |
| Net Cash | 141.29M |
| Retained Earnings | -1.24B |
| Total Assets | 608.58M |
| Working Capital | 275.66M |
Cash Flow
In the last 12 months, operating cash flow was -64.09M and capital expenditures -5.08M, giving a free cash flow of -69.17M.
| Operating Cash Flow | -64.09M |
| Capital Expenditures | -5.08M |
| Free Cash Flow | -69.17M |
| FCF Per Share | -1.19 |
Margins
Gross margin is 42.61%, with operating and profit margins of -70.56% and -66.69%.
| Gross Margin | 42.61% |
| Operating Margin | -70.56% |
| Pretax Margin | -66.51% |
| Profit Margin | -66.69% |
| EBITDA Margin | -56.46% |
| EBIT Margin | -70.56% |
| FCF Margin | -22.1% |
Dividends & Yields
TWST does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -8.66% |
| FCF Yield | -2.79% |
Analyst Forecast
The average price target for TWST is $55.5, which is 33.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $55.5 |
| Price Target Difference | 33.5% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
Scores
| Altman Z-Score | 7.47 |
| Piotroski F-Score | 3 |